Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] · 2026
Pain prescription trends and opioid disorder risk in chronic pancreatitis: A real-world data analysis from 2015 to 2024.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Cai Yanna, Li Jianing, Kong Niwen, Park Walter G, Bi Yan, Pandol Stephen, Jiang Yi
Аннотация
BACKGROUND: Pain in chronic pancreatitis (CP) negatively impacts quality of life and healthcare utilization. This study characterized longitudinal analgesic prescribing trends, demographic differences, treatment pathways, and factors associated with opioid-related outcomes among patients with CP.
METHODS: Using TriNetX, we identified adults with CP and assessed annual incidence and annual period prevalence of documented prescriptions from 2015 to 2024 for: NSAIDs/acetaminophen, opioids, benzodiazepines, neuropathic agents, and muscle relaxants. Treatment pathways and opioid-related outcomes were analyzed using Cox regression models adjusting for 39 covariates.
RESULTS: Among 142,650 CP patients, the annual period prevalence of pain medication prescription increased from 41.24% to 58.80%, substantially exceeding the general population. NSAIDs/acetaminophen and opioid prescription prevalence showed the highest increases. Females exhibited higher use across all medication classes. Younger patients demonstrated higher initiation rates. Initial treatments mostly involved NSAIDs/acetaminophen and opioids, with frequent polypharmacy observed. 10% of patients developed opioid-related conditions, with significantly higher hazards among those with alcohol-related CP (opioid-related disorders: HR = 1.23, 95% CI 1.18-1.29, P < 0.001; opioid dependence: HR = 1.21, 95% CI 1.14-1.27, P < 0.001; opioid abuse: HR = 1.09, 95% CI: 1.02-1.18, p = 0.018) and those undergoing pancreatic surgery (opioid-related disorders: HR = 1.81, 95% CI 1.66-1.96, P < 0.001; opioid dependence: HR = 2.07, 95% CI: 1.89-2.27, p < 0.001).
CONCLUSIONS: This large-scale analysis highlights substantial and increasing analgesic use in CP, marked by increasing opioid prescription burden, polypharmacy, and higher hazards of opioid-related disorders among patients with alcohol-related etiology or pancreatic surgery. These findings emphasize the need for more guideline-concordant, multimodal, and individualized pain management with careful monitoring of high-risk groups.
METHODS: Using TriNetX, we identified adults with CP and assessed annual incidence and annual period prevalence of documented prescriptions from 2015 to 2024 for: NSAIDs/acetaminophen, opioids, benzodiazepines, neuropathic agents, and muscle relaxants. Treatment pathways and opioid-related outcomes were analyzed using Cox regression models adjusting for 39 covariates.
RESULTS: Among 142,650 CP patients, the annual period prevalence of pain medication prescription increased from 41.24% to 58.80%, substantially exceeding the general population. NSAIDs/acetaminophen and opioid prescription prevalence showed the highest increases. Females exhibited higher use across all medication classes. Younger patients demonstrated higher initiation rates. Initial treatments mostly involved NSAIDs/acetaminophen and opioids, with frequent polypharmacy observed. 10% of patients developed opioid-related conditions, with significantly higher hazards among those with alcohol-related CP (opioid-related disorders: HR = 1.23, 95% CI 1.18-1.29, P < 0.001; opioid dependence: HR = 1.21, 95% CI 1.14-1.27, P < 0.001; opioid abuse: HR = 1.09, 95% CI: 1.02-1.18, p = 0.018) and those undergoing pancreatic surgery (opioid-related disorders: HR = 1.81, 95% CI 1.66-1.96, P < 0.001; opioid dependence: HR = 2.07, 95% CI: 1.89-2.27, p < 0.001).
CONCLUSIONS: This large-scale analysis highlights substantial and increasing analgesic use in CP, marked by increasing opioid prescription burden, polypharmacy, and higher hazards of opioid-related disorders among patients with alcohol-related etiology or pancreatic surgery. These findings emphasize the need for more guideline-concordant, multimodal, and individualized pain management with careful monitoring of high-risk groups.